• Facebook
  • Google Plus
  • RSS Feed
  • Twitter

Menu

Skip to content
  • About
  • Staff
  • Contact
  • Support
  • Advertise
  • FAQ
  • Privacy Policy
  • Terms of Service
Header image

Times of San DiegoLogo

Local News and Opinion for San Diego

Menu

Skip to content
  • All
  • Politics
  • Crime
  • Business
  • Sports
  • Education
  • Arts
  • Military
  • Tech
  • Life
  • Opinion
Search Thousands of San Diego Jobs
  • 2,000 Browse Bizarre Bazaar: 'All Things Weird' Expo Kicks Off Tour in Del Mar
  • 2 San Diego Small Businesses Share in $750 Million Cluster of Navy Contracts
  • Police Seek Elderly Man Who Went Missing in Little Italy
  • San Diego State Can't Make Up for Mitchell's Loss, Dropping 2nd Straight to Utah State
  • Motorcyclist Killed on Northbound I-5 Near Las Pulgas Canyon Road

Home » Tech » This Article

San Diego Biopharma Company Announces Promising Results for COVID-19 Treatment

Posted by Debbie L. Sklar on April 2, 2020 in Tech | 1470 Views
| Comments | Leave a Comment
Share This Article:
Facebooktwitterredditpinterestlinkedinmail
Novel coronavirus
An electron microscope image of the new strain of coronavirus. Courtesy of NIAID-RML

A San Diego-based biopharmaceutical company reported promising results Thursday from a clinical trial of COVID-19 treatment conducted in collaboration with Renmin Hospital in Wuhan, China.

Support Times of San Diego's growth
with a small monthly contribution

Become a supporter

Ansun Biopharma said preliminary data showed that DAS181, a drug with antiviral properties, may have contributed to the reduction and elimination of COVID-19 symptoms in four patients suffering from severe bilateral viral pneumonia and hypoxemia.

The patients were given a 10-day treatment regimen of nebulized DAS181, according to Ansun.

“These results are highly encouraging, as they demonstrate that DAS181 may potentially help reduce or eliminate some of the most significant symptoms associated with COVID-19,” said Dr. Zuojiong Gong and De. Ke Hu, the study’s principal investigators at Renmin Hospital.

“In the first 14 days of our study, the first two patients no longer required supplemental oxygen, and showed stabilized vital signs, increased oxygen saturation, and resolution of infiltrates on chest CT scans. The third patient, who had been a persistent SARS-CoV-2 carrier for more than 33 days, was completely virus-free before the end of the 10-day DAS181 regimen and met all discharge criteria, and the fourth is currently undergoing treatment and showing positive trends.”

Ansun is slated to conduct a two-stage trial of the drug in the United States, with an initial enrollment of around 20 patients at various U.S. medical centers. The study will be conducted to determine DAS181’s safety and efficacy in treating severe COVID-19 pneumonia, according to the company.

Ansun CEO Dr. Nancy Chung said, “We are excited about the preliminary data generated by our partners at Wuhan University, and we believe this is an important step towards determining the potential clinical utility of DAS181 at this critical time. Unlike other therapeutic approaches, DAS181 may inhibit the virus through multiple potential mechanisms of action including modifications of the host receptor, interference with endocytosis, prevention of cell-to-cell spread and immunomodulation.”

Currently, there are no approved treatments available to patients with severe SARS-CoV-2 inducted pneumonia.

–City News Service

San Diego Biopharma Company Announces Promising Results for COVID-19 Treatment was last modified: April 3rd, 2020 by Debbie L. Sklar

>> Subscribe to Times of San Diego’s free daily email newsletter! Click here

Follow Us:
Facebooktwitterrss
Posted in Tech | Tagged Ansun BioPharma, COVID-19, results, San Diego, treatment
Search Thousands of San Diego Jobs

Get Times of San Diego by Email

Our free newsletter is delivered at 8 a.m. daily.


Most Popular Today

  • New CDC Data Shows How San Diego County Ranks Nationally in the Pandemic New CDC Data Shows How San Diego County Ranks Nationally in the Pandemic 1,610 views
  • Opinion: Santee's Dustin Trotter Should Resign as Backer of D.C. Insurrectionists Opinion: Santee’s Dustin Trotter Should Resign as Backer of D.C. Insurrectionists 920 views
  • MarketInk: Prolific Announcer Hangs Up Microphone After 2,000 Games Over 35 Years MarketInk: Prolific Announcer Hangs Up Microphone After 2,000 Games Over 35 Years 900 views
  • San Diego Residents 65+ Are Next in Line for Vaccine, But Supplies Still Limited San Diego Residents 65+ Are Next in Line for Vaccine, But Supplies Still Limited 560 views
  • Nazi Flag Driver, an Iraq Combat Veteran, Has Gun Violence Restraining Order Nazi Flag Driver, an Iraq Combat Veteran, Has Gun Violence Restraining Order 490 views

©®2021 Times of San Diego LLC

Menu

  • About
  • Staff
  • Contact
  • Support
  • Advertise
  • FAQ
  • Privacy Policy
  • Terms of Service